| Market Cap | 8.42M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -20.77M | Forward P/E | -0.21 | EPS next Y | - | 50D Avg Chg | -23.00% |
| Sales | 50k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
| Dividend | N/A | Price/Book | 0.46 | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 3.00 | Quick Ratio | 0.13 | Shares Outstanding | 8.61M | 52W Low Chg | 39.00% |
| Insider Own | 0.18% | ROA | -30.20% | Shares Float | 2.92M | Beta | -3.25 |
| Inst Own | 26.48% | ROE | -148.27% | Shares Shorted/Prior | 135.22K/161.74K | Price | 0.50 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 441,519 | Target Price | - |
| Oper. Margin | -41,466.00% | Earnings Date | May 14 | Volume | 391,324 | Change | -3.78% |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brenner Martin | See Remarks See Remarks | May 22 | Sell | 0.94 | 4,182 | 3,931 | 257,595 | 05/24/23 |